Abstract
In this chapter, various altered fractionation schedules are categorized and discussed within the landscape of clinical trials. Today, modern radiotherapy (RT) techniques are offering new avenues to exploit the advantages of altered fractionation not only for the primary treatment of treatment-naïve patients, but also in reirradiation and palliative situations. Novel agents, which are at least as effective but less toxic than platinum compounds, can be combined with contemporary RT techniques to widen the therapeutic window. Radiotherapy with altered fractionation, both alone or as part of combined modalities with systemic therapy (ST), offers many opportunities to the head and neck oncologists.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Al-Mamgani A, van Rooij PH, Woutersen DP et al (2013a) Radiotherapy for T1-2N0 glottic cancer: a multivariate analysis of predictive factors for the long-term outcome in 1050 patients and a prospective assessment of quality of life and voice handicap index in a subset of 233 patients. Clin Otolaryngol 38:306–312. doi:10.1111/coa.12139
Al-Mamgani A, Van Rooij P, Sewnaik A et al (2013b) Brachytherapy or stereotactic body radiotherapy boost for early-stage oropharyngeal cancer: comparable outcomes of two different approaches. Oral Oncol 49:1018–1024. doi:10.1016/j.oraloncology.2013.07.007
Al-Mamgani A, Kwa SLS, Tans L et al (2015) Single vocal cord irradiation: image guided intensity modulated hypofractionated radiation therapy for T1a glottic cancer: early clinical results. Int J Radiat Oncol Biol Phys 93:337–343. doi:10.1016/j.ijrobp.2015.06.016
Argiris A, Li Y, Forastiere A (2004) Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 101:2222–2229. doi:10.1002/cncr.20640
Bartelink H, Van den Bogaert W, Horiot JC et al (2002) Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomized phase II EORTC trial. Eur J Cancer 38:667–673. doi:10.1016/S0959-8049(01)00425-7
Baujat B, Bourhis J, Blanchard P et al (2010) Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev:CD002026. doi:10.1002/14651858.CD002026
Beitler JJ, Zhang Q, Fu KK et al (2014) Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys 89:13–20. doi:10.1016/j.ijrobp.2013.12.027
Bentzen SM, Trotti A (2007) Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 25:4096–4103. doi:10.1200/JCO.2007.13.3983
Blanchard P, Hill C, Guihenneuc-Jouyaux C et al (2011) Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer. J Clin Epidemiol 64:985–992. doi:10.1016/j.jclinepi.2010.10.016
Blanchard P, Lee A, Marguet S et al (2015) Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol 16:645–655. doi:10.1016/S1470-2045(15)70126-9
Bonner J, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578. doi:10.1056/NEJMoa053422
Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28. doi:10.1016/S1470-2045(09)70311-0
Bourhis J, Overgaard J, Audry H et al (2006a) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368:843–854. doi:10.1016/S0140-6736(06)69121-6
Bourhis J, Lapeyre M, Tortochaux J et al (2006b) Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol 24:2873–2878. doi:10.1200/JCO.2006.08.057
Bourhis J, Sire C, Graff P et al (2012) Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomized trial. Lancet Oncol 13:145–153. doi:10.1016/S1470-2045(11)70346-1
Bradley J, Paulson ES, Ahunbay E et al (2011) Dynamic MRI analysis of tumor and organ motion during rest and deglutition and margin assessment for radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys 81:e803–e812. doi:10.1016/j.ijrobp.2010.12.015
Budach W, Hehr T, Budach V et al (2006) A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6:28. doi:10.1186/1471-2407-6-28
Carvalho AL, Nishimoto IN, Califano JA et al (2005) Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 114:806–816. doi:10.1002/ijc.20740
Chen AM, Vaughan A, Narayan S, Vijayakumar S (2008) Palliative radiation therapy for head and neck cancer: toward an optimal fractionation scheme. Head Neck 30:1586–1591. doi:10.1002/hed.20894
Chen AM, Farwell DG, Luu Q et al (2011) Prospective trial of high-dose reirradiation using daily image guidance with intensity-modulated radiotherapy for recurrent and second primary head-and-neck cancer. Int J Radiat Oncol Biol Phys 80:669–676. doi:10.1016/j.ijrobp.2010.02.023
Chera BS, Amdur RJ, Morris CG et al (2010a) T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 78:461–466. doi:10.1016/j.ijrobp.2009.08.066
Chera BS, Amdur RJ, Morris CG et al (2010b) Carotid-sparing intensity-modulated radiotherapy for early-stage squamous cell carcinoma of the true vocal cord. Int J Radiat Oncol Biol Phys 77:1380–1385. doi:10.1016/j.ijrobp.2009.07.1687
Chitapanarux I, Tharavichitkul E, Kamnerdsupaphon P et al (2013) Randomized phase III trial of concurrent chemoradiotherapy vs accelerated hyperfractionation radiotherapy in locally advanced head and neck cancer. J Radiat Res 54:1110–1117. doi:10.1093/jrr/rrt054
Cooper JS, Pajak TF, Rubin P et al (1989) Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 17:449–456
Corry J, Peters LJ, D’Costa I et al (2005) The “QUAD SHOT” - A phase II study of palliative radiotherapy for incurable head and neck cancer. Radiother Oncol 77:137–142. doi:10.1016/j.radonc.2005.10.008
Cummings B, Keane T, Pintilie M et al (2007) Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. Radiother Oncol 85:7–16. doi:10.1016/j.radonc.2007.09.010
Curran D, Giralt J, Harari PM et al (2007) Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25:2191–2197. doi:10.1200/JCO.2006.08.8005
Dakubo GD, Jakupciak JP, Birch-Machin MA et al (2007) Clinical implications and utility of field cancerization. Cancer Cell Int 7:2. doi:10.1186/1475-2867-7-2
De Crevoisier R, Domenge C, Wibault P et al (2001) Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. Cancer 91:2071–2076. doi:10.1002/1097-0142(20010601)91:11<2071::AID-CNCR1234>3.0.CO;2-Z
Devaiah A, Murchison C (2016a) Analysis of 473 US head and neck cancer trials (1996–2014): trends, gaps, and opportunities. Otolaryngol Head Neck Surg 154:309–314. doi:10.1177/0194599815617723
Devaiah A, Murchison C (2016b) Characteristics of NIH- and industry-sponsored head-and-neck cancer clinical trials. Laryngoscope 1–4. doi:10.1002/lary.25942
Dische S, Saunders M, Barrett A et al (1997) A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 44:123–136. doi:10.1016/S0167-8140(97)00094-7
Dobrowsky W, Naudé J (2000) Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. Radiother Oncol 57:119–124
Dorresteijn LDA, Kappelle AC, Boogerd W et al (2002) Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. J Clin Oncol 20:282–288
Ermiş E, Teo M, Dyker KE et al (2015) Definitive hypofractionated radiotherapy for early glottic carcinoma: experience of 55Gy in 20 fractions. Radiat Oncol 10:203. doi:10.1186/s13014-015-0505-6
Feigenberg S, Patel K, Amdur RJ et al (2014) RTOG 9003: the untold story. Int J Radiat Oncol Biol Phys 90:251–252. doi:10.1016/j.ijrobp.2014.04.043
Ferlay J, Shin H-R, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917. doi:10.1002/ijc.25516
Ferris RL, Blumenschein G, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. doi:10.1056/NEJMoa1602252
Fu KK, Pajak TF, Marcial V et al (1995) Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. Int J Radiat Oncol Biol Phys 32:577–588. doi:10.1016/0360-3016(95)00080-I
Fu KK, Pajak TF, Trotti A et al (2000) A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7–16
Garden AS, Forster K, Wong PF et al (2003) Results of radiotherapy for T2N0 glottic carcinoma: does the “2” stand for twice-daily treatment? Int J Radiat Oncol Biol Phys 55:322–328. doi:10.1016/S0360-3016(02)03938-X
Ghaly M, Halthore A, Antone J et al (2014) Dose-escalated stereotactic radiosurgery (SRS) boost for unfavorable locally advanced oropharyngeal cancer: phase I/II trial. Int J Radiat Oncol 90:S122. doi:10.1016/j.ijrobp.2014.05.559
Ghosh-Laskar S, Chaukar D, Deshpande M et al (2016a) Phase III randomized trial of surgery followed by conventional radiotherapy (5 fr/Wk) (Arm A) vs concurrent chemoradiotherapy (Arm B) vs accelerated radiotherapy (6fr/Wk) (Arm C) in locally advanced, stage III and IV, resectable, squamous cell carcinoma oral cavity- oral cavity adjuvant therapy (OCAT): final results (NCT00193843). J Clin Oncol:6004
Good JS, Harrington KJ (2013) The hallmarks of cancer and the radiation oncologist: updating the 5Rs of radiobiology. Clin Oncol 25:569–577. doi:10.1016/j.clon.2013.06.009
Gujral DM, Miah AB, Bodla S et al (2014) Final long-term results of a phase I/II study of dose-escalated intensity-modulated radiotherapy for locally advanced laryngo-hypopharyngeal cancers. Oral Oncol 50:1089–1097. doi:10.1016/j.oraloncology.2014.07.018
Gupta T, Kannan S, Ghosh-Laskar S et al (2015) Concomitant chemoradiotherapy versus altered fractionation radiotherapy in the radiotherapeutic management of loco-regionally advanced head and neck squamous cell carcinoma: an adjusted indirect comparison meta-analysis. Head Neck 37:670–676. doi:10.1002/hed.23661
Gupta T, Kannan S, Ghosh-Laskar S, Agarwal JP (2016) Systematic review and meta-analysis of conventionally fractionated concurrent chemoradiotherapy versus altered fractionation radiotherapy alone in the definitive management of loco-regionally advanced head and neck squamous cell carcinoma. Clin Oncol (R Coll Radiol) 28:50–61. doi:10.1016/j.clon.2015.09.002
Hitt R, Grau JJ, López-Pousa A et al (2014) A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 25:216–225. doi:10.1093/annonc/mdt46
Hliniak A, Gwiazdowska B, Szutkowski Z et al (2002) A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1-week shortening overall time. Radiother Oncol 62:1–10. doi:10.1016/S0167-8140(01)00494-7
Horiot JC, Le Fur R, N’Guyen T et al (1992) Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25:231–241
Horiot JC, Bontemps P, van den Bogaert W et al (1997) Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 44:111–121
Janot F, de Raucourt D, Benhamou E et al (2008) Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 26:5518–5523. doi:10.1200/JCO.2007.15.0102
Krstevska V, Crvenkova S (2006) Altered and conventional fractionated radiotherapy in locoregional control and survival of patients with squamous cell carcinoma of the larynx, oropharynx, and hypopharynx. Croat Med J 47:42–52
Kwa SLS, Al-Mamgani A, Osman S et al (2015) Inter- and intrafraction target motion in highly focused single vocal cord irradiation of T1a larynx cancer patients. Int J Radiat Oncol Biol Phys 93:190–195. doi:10.1016/j.ijrobp.2015.04.049
Langendijk JA, Kasperts N, Leemans CR et al (2006) A phase II study of primary reirradiation in squamous cell carcinoma of head and neck. Radiother Oncol 78:306–312. doi:10.1016/j.radonc.2006.02.003
Langer C, Harris J, Horwitz E et al (2007) Phase II study of low dose Paclitaxel and Cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamoius cell carcinoma of the head and neck: results of RTOG Protocol 9911. J Clin Oncol 25:4800–4805
Lassen P, Eriksen JG, Krogdahl A et al (2011) The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomized DAHANCA 6&7 trial. Radiother Oncol 100:49–55. doi:10.1016/j.radonc.2011.02.010
Lee AWM, Tung SY, Chan ATC et al (2011) A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Radiother Oncol 98:15–22. doi:10.1016/j.radonc.2010.09.023
Lee AWM, Ngan RKC, Tung SY et al (2015) Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy. Cancer 121:1328–1338. doi:10.1002/cncr.29208
Ling DC, Vargo JA, Heron DE (2016a) Stereotactic body radiation therapy for recurrent head and neck cancer. Cancer J 22:302–306. doi:10.1097/PPO.0000000000000208
Liu Z, Huang S, Zhang D (2013) High dose rate versus low dose rate brachytherapy for oral cancer--a meta-analysis of clinical trials. PLoS One 8:e65423. doi:10.1371/journal.pone.0065423
Lok BH, Jiang G, Gutiontov S et al (2015) Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers. Oral Oncol 51:957–962. doi:10.1016/j.oraloncology.2015.07.011
Lyhne NM, Primdahl H, Kristensen C et al (2015) The DAHANCA 6 randomized trial: effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma. Radiother Oncol 117:91–98. doi:10.1016/j.radonc.2015.07.004
Lyhne NM, Johansen J, Kristensen CA et al (2016) Pattern of failure in 5001 patients treated for glottic squamous cell carcinoma with curative intent - A population based study from the DAHANCA group. Radiother Oncol 118:257–266. doi:10.1016/j.radonc.2016.02.006
Marcial VA, Pajak TF, Chang C et al (1987) Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology. Int J Radiat Oncol Biol Phys 13:41–47
Mohanti BK, Nachiappan P, Pandey RM et al (2007) Analysis of 2167 head and neck cancer patients’ management, treatment compliance and outcomes from a regional cancer centre, Delhi, India. J Laryngol Otol 121:49–56. doi:10.1017/S0022215106002751
Moon SH, Cho KH, Chung EJ et al (2013) A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study. Radiother Oncol 110:98–103. doi:10.1016/j.radonc.2013.09.016
Mortensen HR, Overgaard J, Specht L et al (2012) Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomized trial with accelerated radiotherapy for head and neck cancer. Radiother Oncol 103:69–75. doi:10.1016/j.radonc.2012.01.002
Nguyen-Tan PF, Zhang Q, Ang KK et al (2014) Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol 32:3858–3866. doi:10.1200/JCO.2014.55.3925
Overgaard J, Hjelm-Hansen M, Johansen LV et al (1988) Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx. Acta Oncol 27:147–152. doi:10.3109/02841868809090334
Overgaard J, Hansen HS, Andersen AP et al (1989) Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 16:1065–1068
Overgaard J, Hansen HS, Specht L et al (2003) Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomized controlled trial. Lancet (London, England) 362:933–940
Overgaard J, Mohanti BK, Begum N et al (2010) Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomized, multicentre trial. Lancet Oncol 11:553–560. doi:10.1016/S1470-2045(10)70072-3
Pehlivan B, Luthi F, Matzinger O et al (2009) Feasibility and efficacy of accelerated weekly concomitant boost postoperative radiation therapy combined with concomitant chemotherapy in patients with locally advanced head and neck cancer. Ann Surg Oncol 16:1337–1343. doi:10.1245/s10434-009-0426-4
Peters LJ, Ang KK, Thames HD (1988) Accelerated fractionation in the radiation treatment of head and neck cancer. A critical comparison of different strategies. Acta Oncol 27:185–194. doi:10.3109/02841868809090339
Pignon J-P, le Maître A, Maillard E et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomized trials and 17,346 patients. Radiother Oncol 92:4–14. doi:10.1016/j.radonc.2009.04.014
Pinto LH, Canary PC, Araújo CM et al (1991) Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 21:557–562. doi:10.1016/0360-3016(91)90670-Y
Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705–1715. doi:10.1056/NEJMoa070956
Quan K, Xu KM, Zhang Y et al (2016) Toxicities following stereotactic ablative radiotherapy treatment of locally-recurrent and previously irradiated head and neck squamous cell carcinoma. Semin Radiat Oncol 26:112–119. doi:10.1016/j.semradonc.2015.11.007
Rischin D, Ferris RL, Le Q-T (2015) Overview of advances in head and neck cancer. J Clin Oncol 33:3225–3226. doi:10.1200/JCO.2015.63.6761
Rishi A, Ghoshal S, Verma R et al (2013) Comparison of concomitant boost radiotherapy against concurrent chemoradiation in locally advanced oropharyngeal cancers: a phase III randomized trial. Radiother Oncol 107:317–324. doi:10.1016/j.radonc.2013.05.016
Rosenthal DI, Fuller CD, Peters LJ et al (2015) Final report of radiation therapy oncology group protocol 9003: provocative, but limited conclusions from exploratory analyses. Int J Radiat Oncol Biol Phys 92:715–717. doi:10.1016/j.ijrobp.2015.02.051
Sakata K, Someya M, Hori M et al (2008) Hyperfractionated accelerated radiotherapy for T1, 2 glottic carcinoma. Consideration of time-dose factors. Strahlenther Onkol 184:364–369. doi:10.1007/s00066-008-1819-1
Sanchíz F, Milla A, Torner J et al (1990) Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 19:1347–1350. doi:10.1016/0360-3016(90)90342-H
Saunders MI, Rojas AM, Parmar MKB et al (2010) Mature results of a randomized trial of accelerated hyperfractionated versus conventional radiotherapy in head-and-neck cancer. Int J Radiat Oncol Biol Phys 77:3–8. doi:10.1016/j.ijrobp.2009.04.082
Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29. doi:10.3322/caac.21254
Skladowski K, Maciejewski B, Golen M et al (2000) Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity. Radiother Oncol 55:101–110. doi:10.1016/S0167-8140(00)00139-0
Skladowski K, Maciejewski B, Golen M et al (2006) Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of Phase III clinical trial. Int J Radiat Oncol Biol Phys 66:706–713. doi:10.1016/j.ijrobp.2006.05.026
Skladowski K, Hutnik M, Wygoda A et al (2013) Radiation-free weekend rescued! Continuous accelerated irradiation of 7-days per week is equal to accelerated fractionation with concomitant boost of 7 fractions in 5-days per week: report on phase 3 clinical trial in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 85:741–746. doi:10.1016/j.ijrobp.2012.06.037
Smith GL, Smith BD, Buchholz T et al (2008) Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy. J Clin Oncol 26:5119–5125. doi:10.1200/JCO.2008.16.6546
Spanos WT, Clery M, Perez CA et al (1994) Late effect of multiple daily fraction palliation schedule for advanced pelvic malignancies (RTOG 8502). Int J Radiat Oncol Biol Phys 29:961–967. doi:10.1016/0360-3016(94)90389-1
Spencer SA, Harris J, Wheeler RH et al (2008) Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 30:281–288. doi:10.1002/hed.20697
Suwiński R, Bańkowska-Woźniak M, Majewski W et al (2008) Randomized clinical trial on 7-days-a-week postoperative radiotherapy for high-risk squamous cell head and neck cancer. Radiother Oncol 87:155–163. doi:10.1016/j.radonc.2008.02.009
Tao Y, Aupérin A, Graff P et al (2016) Concurrent chemoradiation therapy versus acceleration of radiation therapy with or without concurrent chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): 7-year survival data from a phase 3 randomized trial and prognostic factors. Int J Radiat Oncol Biol Phys 96:E324–E325. doi:10.1016/j.ijrobp.2016.06.1443
Teo PM, Leung SF, Chan AT et al (2000) Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications. Int J Radiat Oncol Biol Phys 48:1311–1322. doi:10.1016/S0360-3016(00)00786-0
Thames HD, Bentzen SM, Turesson I et al (1989) Fractionation parameters for human tissues and tumors. Int J Radiat Biol 56:701–710
Trotti A, Machtay M (2014) RTOG 9003: legacies of a landmark trial. Int J Radiat Oncol Biol Phys 90:253–254. doi:10.1016/j.ijrobp.2014.07.022
Trotti A, Pajak TF, Gwede CK et al (2007) TAME: development of a new method for summarizing adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol 8:613–624. doi:10.1016/S1470-2045(07)70144-4
Trotti A, Zhang Q, Bentzen SM et al (2014) Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512). Int J Radiat Oncol Biol Phys 89:958–963. doi:10.1016/j.ijrobp.2014.04.041
Van Asselen B, Raaijmakers CPJ, Lagendijk JJW et al (2003) Intrafraction motions of the larynx during radiotherapy. Int J Radiat Oncol Biol Phys 56:384–390. doi:10.1016/S0360-3016(02)04572-8
Vargo JA, Ferris RL, Ohr J et al (2015) A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 91:480–8. doi: 10.1016/j.ijrobp.2014.11.023
Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127. doi:10.1056/NEJMoa0802656
Weissberg JB, Son YH, Percarpio B et al (1982) Randomized trial of conventional versus high fractional dose radiation therapy in the treatment of advanced head and neck cancer. Int J Radiat Oncol Biol Phys 8:179–185
Yamamoto E, Shibuya H, Yoshimura R et al (2002) Site specific dependency of second primary cancer in early stage head and neck squamous cell carcinoma. Cancer 94:2007–2014. doi:10.1002/cncr.10444
Yamazaki H, Nishiyama K, Tanaka E et al (2006) Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys 64:77–82. doi:10.1016/j.ijrobp.2005.06.014
Yamoah K, Showalter TN, Ohri N (2015) Radiation therapy intensification for solid tumors: a systematic review of randomized trials. Int J Radiat Oncol Biol Phys 93:737–745. doi:10.1016/j.ijrobp.2015.07.2284
Additional References for Tables
Ang KK, Trotti A, Brown BW et al (2001) Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 51:571–578. doi:10.1016/S0360-3016(01)01690-X
Ang KK, Harris J, Garden AS et al (2005) Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation Therapy Oncology Group Phase II Trial 99-14. J Clin Oncol 23:3008–3015. doi:10.1200/JCO.2005.12.060
Awwad HK, Khafagy Y, Barsoum M et al (1992) Accelerated versus conventional fractionation in the postoperative irradiation of locally advanced head and neck cancer: influence of tumour proliferation. Radiother Oncol 25:261–266. doi:10.1016/0167-8140(92)90245-P
Awwad HK, Lotayef M, Shouman T et al (2002) Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the postoperative radiotherapy of locally advanced head and neck cancer: influence of proliferation. Br J Cancer 86:517–523. doi:10.1038/sj.bjc.6600119
Bensadoun R-JJ, Benezery K, Dassonville O et al (2006) French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 64:983–994. doi:10.1016/j.ijrobp.2005.09.041
Bentzen J, Toustrup K, Eriksen JG et al (2015) Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study. Acta Oncol 54:1001–1007. doi:10.3109/0284186X.2014.992547
Bourhis J, Lapeyre M, Tortochaux J et al (2011) Accelerated radiotherapy and concomitant high dose chemotherapy in non-resectable stage IV locally advanced HNSCC: results of a GORTEC randomized trial. Radiother Oncol 100:56–61. doi:10.1016/j.radonc.2011.07.006
Brizel DM, Albers ME, Fisher SR et al (1998) Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798–1804. doi:10.1056/NEJM199806183382503
Budach V, Stuschke M, Budach W et al (2005) Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 23:1125–1135. doi:10.1200/JCO.2005.07.010
Budach V, Stromberger C, Poettgen C et al (2015) Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial. Int J Radiat Oncol Biol Phys 91:916–924. doi:10.1016/j.ijrobp.2014.12.034
Cvek J, Kubes J, Skacelikova E et al (2012) Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70-75 Gy in 5 weeks for advanced head and neck cancer: a phase I dose escalation study. Strahlenther Onkol 188:666–670. doi:10.1007/s00066-012-0128-x
Daoud J, Toumi N, Siala W et al (2007) Results of a prospective randomised trial comparing conventional radiotherapy to split-course bifractionated radiation therapy in patients with nasopharyngeal carcinoma. Radiother Oncol 85:17–23. doi:10.1016/j.radonc.2007.01.013
Eisbruch A, Harris J, Garden AS et al (2010) Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys 76:1333–1338. doi:10.1016/j.ijrobp.2009.04.011
Ezzat M, Shouman T, Zaza K et al (2005) A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer. J Egypt Natl Canc Inst 17:85–92
Garden AS, Harris J, Trotti A et al (2008) Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys 71:1351–1355. doi:10.1016/j.ijrobp.2008.04.006
Ghadjar P, Simcock M, Studer G et al (2012) Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94). Int J Radiat Oncol Biol Phys 82:524–531. doi:10.1016/j.ijrobp.2010.11.067
Ghoshal S, Goda JS, Mallick I et al (2008) Concomitant boost radiotherapy compared with conventional radiotherapy in squamous cell carcinoma of the head and neck--a phase III trial from a single institution in India. Clin Oncol 20:212–220. doi:10.1016/j.clon.2008.01.011
Ghosh-Laskar S, Kalyani N, Gupta T et al (2016b) Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in loco-regionally advanced carcinoma of head and neck: results of a prospective randomized trial. Head Neck 38:202–207. doi:10.1002/hed.23865
Gunn GB, Endres EJ, Parker B et al (2010) A phase I/II study of altered fractionated IMRT alone for intermediate t-stage oropharyngeal carcinoma. Strahlenther Onkol 186:489–495. doi:10.1007/s00066-010-2093-6
Hassan Metwally MA, Ali R, Kuddu M et al (2015) IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma. Radiother Oncol 116:15–20. doi:10.1016/j.radonc.2015.04.005
Heron DE, Ferris RL, Karamouzis M et al (2009) Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys 75:1493–1500. doi:10.1016/j.ijrobp.2008.12.075
Huguenin P, Beer KT, Allal A et al (2004) Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 22:4665–4673. doi:10.1200/JCO.2004.12.193
Iwata H, Tatewaki K, Inoue M et al (2012) Salvage stereotactic reirradiation using the CyberKnife for the local recurrence of nasal or paranasal carcinoma. Radiother Oncol 104:355–360. doi:10.1016/j.radonc.2012.01.017
Jackson SM, Weir LM, Hay JH et al (1997) A randomized trial of accelerated versus conventional radiotherapy in head and neck cancer. Radiother Oncol 43:39–46
Janssens GO, Rademakers SE, Terhaard CH et al (2012) Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol 30:1777–1783. doi:10.1200/JCO.2011.35.9315
Jeremic B, Shibamoto Y, Milicic B et al (2000) Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18:1458–1464
Johnson CR, Schmidt-Ullrich RK, Arthur DW et al (1995) 42 Standard Once daily versus thrice-daily concomitant boost accelerated superfractionated irradiation for advanced squamous cell carcinoma of the head and neck: preliminary results of a prospective randomized trial. Int J Radiat Oncol 32:162. doi:10.1016/0360-3016(95)97707-8
Kao J, Genden EM, Gupta V et al (2011) Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer. Cancer 117:318–326. doi:10.1002/cncr.25374
Lartigau EF, Tresch E, Thariat J et al (2013) Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer. Radiother Oncol 109:281–285. doi:10.1016/j.radonc.2013.08.012
Lee AWM, Tung SY, Chan ATC et al (2006) Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 66:142–151. doi:10.1016/j.ijrobp.2006.03.054
Ling DC, Vargo JA, Ferris RL et al (2016b) Risk of severe toxicity according to site of recurrence in patients treated with stereotactic body radiation therapy for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 95:973–980. doi:10.1016/j.ijrobp.2016.02.049
Maguire PD, Papagikos M, Hamann S et al (2011) Phase II trial of hyperfractionated intensity-modulated radiation therapy and concurrent weekly cisplatin for stage III and IVa head-and-neck cancer. Int J Radiat Oncol Biol Phys 79:1081–1088. doi:10.1016/j.ijrobp.2009.12.046
Miszczyk L, Maciejewski B, Tukiendorf A et al (2014) Split-course accelerated hyperfractionated irradiation (CHA-CHA) as a sole treatment for advanced head and neck cancer patients-final results of a randomized clinical trial. Br J Radiol 87:20140212. doi:10.1259/bjr.20140212
Nyqvist J, Fransson P, Laurell G et al (2016) Differences in health related quality of life in the randomized ARTSCAN study; accelerated vs. conventional radiotherapy for head and neck cancer. A five year follow up. Radiother Oncol 118:335–341. doi:10.1016/j.radonc.2015.12.024
Olmi P, Crispino S, Fallai C et al (2003) Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial. Int J Radiat Oncol Biol Phys 55:78–92. doi:10.1016/S0360-3016(02)03792-6
Poulsen MG, Denham JW, Peters LJ et al (2001) A randomized trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study. Radiother Oncol 60:113–122. doi:10.1016/S0167-8140(01)00347-4
Sanguineti G, Richetti A, Bignardi M et al (2005) Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter phase III study. Int J Radiat Oncol Biol Phys 61:762–771. doi:10.1016/j.ijrobp.2004.07.682
Songthong AP, Kannarunimit D, Chakkabat C et al (2015) A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events. Radiat Oncol 10:166. doi:10.1186/s13014-015-0472-y
Staar S, Rudat V, Stuetzer H et al (2001) Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy - Results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50:1161–1171. doi:10.1016/S0360-3016(01)01544-9
Stuschke M, Thames HD (1997) Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys 37:259–267. doi:10.1016/S0360-3016(96)00511-1
Suwinski R, Wozniak G, Misiolek M et al (2016) Randomized clinical trial on 7-days-a-week post-operative radiotherapy vs concurrent post-operative radiochemotherapy in locally advanced cancer of the oral cavity/oropharynx: a report on acute normal tissue reactions. Br J Radiol 89:20150805. doi:10.1259/bjr.20150805
Wendt TG, Grabenbauer GG, Rödel CM et al (1998) Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 16:1318–1324
Zackrisson B, Kjellén E, Söderström K et al (2015) Mature results from a Swedish comparison study of conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma - The ARTSCAN trial. Radiother Oncol 117:99–105. doi:10.1016/j.radonc.2015.09.024
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Elicin, O., Mahmut Ozsahin, E. (2017). Head and Neck Cancer. In: Trombetta, M., Pignol, JP., Montemaggi, P., Brady, L.W. (eds) Alternate Fractionation in Radiotherapy. Medical Radiology(). Springer, Cham. https://doi.org/10.1007/174_2017_32
Download citation
DOI: https://doi.org/10.1007/174_2017_32
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-51197-9
Online ISBN: 978-3-319-51198-6
eBook Packages: MedicineMedicine (R0)